NCT05931276View on ClinicalTrials.gov

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

PHASE3RecruitingINTERVENTIONAL
Enrollment

2,540

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
End-Stage Kidney DiseaseEnd-Stage Renal Disease
Interventions
DRUG

Metoprolol Succinate

a dialyzable, beta-1 selective beta blocker

DRUG

Carvedilol

a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties

Trial Locations (2)

02130-4817

NOT_YET_RECRUITING

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston

55417-2309

RECRUITING

Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis

All Listed Sponsors
lead

VA Office of Research and Development

FED